{"ticker": {"uuid": "23e1fdd6-70b0-4017-a710-2505bdd11680", "symbol": "OCGN", "name": "Ocugen Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ocugen Inc. stock rises Tuesday, outperforms market", "summary": "Shares of Ocugen Inc. (OCGN) rose on Tuesday, gaining 1.42% to close at $1.43. This performance outpaced the broader market, as the S&P 500 Index and the Dow Jones Industrial Average also saw increases. Despite the rise, Ocugen Inc. remains 47.52% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-tuesday-outperforms-market-3f5a5f8d-f9b41f6b5309", "source_name": "MarketWatch", "published_at": "2026-07-14T17:27:00", "published_display": "14 Jul 2026 17:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Monday, underperforms market", "summary": "Ocugen Inc. (OCGN) stock fell 4.08% on Monday, closing at $1.41, underperforming the broader market as the S&P 500 and Dow Jones also experienced declines. The company's stock is currently 48.26% below its 52-week high of $2.73, achieved on March 17th.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-monday-underperforms-market-a13eca2e-cc40f435f2ea", "source_name": "MarketWatch", "published_at": "2026-07-13T17:28:00", "published_display": "13 Jul 2026 17:28", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa", "summary": "Ocugen, Inc. has announced a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license OCU400, a modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. The agreement includes potential sales mileston", "url": "https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-binding-term-sheet-roots-pharmaceutical/", "source_name": "Ocugen, Inc.", "published_at": "2026-07-13T15:10:42", "published_display": "13 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbnQtNVJfQ3A3SFUxMUp2OUxaaUNuWDNINFU2NXZqWDJZWE9ZcHVIdnhyZkZfNHYxVUNGcTE3d2taanN5dHd1ekZaLVRaYUxIQS0yMWhqdHRtV3pSenZUUjNDZ0xwYWtRMXdkRWE5MHpqWnlzRXZKM1FqZHdJcmVYcnpiZlM4Y04zQ3NRT190LWxBQ3BDdFpZRGdvZVQwX0daTC04Rk4wZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T12:07:18+00:00", "published_display": "13 Jul 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region", "summary": "Ocugen has signed a term sheet to license its retinitis pigmentosa gene therapy, OCU400, to Roots Pharmaceutical and Al-Dhow for commercialization in the MENA region. This agreement, facilitated by a joint venture between the two MENA companies, aims to bring OCU400 to patients w", "url": "https://www.moomoo.com/news/post/72859257/ocugen-signs-term-sheet-to-license-retinitis-pigmentosa-gene-therapy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T12:10:43", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Ocugen, Inc. Reports Material Event", "summary": "Ocugen, Inc. announced it has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to negotiate an exclusive license for its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa. The deal could bring Ocugen u", "url": "https://www.stocktitan.net/sec-filings/OCGN/8-k-ocugen-inc-reports-material-event-8b91c8a4fa57.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:42", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen signs OCU400 MENA license agreement", "summary": "Ocugen has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding for the exclusive licensing rights of its investigational gene therapy OCU400 in the Middle East and North Africa (MENA) region. This potential agreement could bring Ocugen up to $4", "url": "https://grafa.com/en/news/united-states/ocugen-ocu400-mena-license-agreement-retinitis-pigmentosa", "source_name": "grafa.com", "published_at": "2026-07-13T11:38:00", "published_display": "13 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene therapy for inherited blindness set for MENA launch under Ocugen\u2013Roots pact", "summary": "Ocugen (NASDAQ: OCGN) has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa (MENA) region. The agreement is expected to include up to $4 ", "url": "https://www.stocktitan.net/news/OCGN/ocugen-inc-announces-binding-term-sheet-with-roots-pharmaceutical-to-2xzd3dhb2bm7.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:10:43", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances", "summary": "Ocugen (NASDAQ:OCGN) plans to submit three biologics license applications (BLAs) for its late-stage retinal gene therapies, targeting retinitis pigmentosa and Stargardt disease next year, and geographic atrophy in 2028. The company expects to deliver two top-line readouts in 2025", "url": "https://finance.yahoo.com/healthcare/articles/ocugen-eyes-3-retinal-gene-000206047.html", "source_name": "Market source", "published_at": "2026-07-11T00:09:47", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Thursday, underperforms market", "summary": "Ocugen Inc. (OCGN) stock fell 2.00% on Thursday, closing at $1.47, despite an overall positive trading day for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, while Ocugen Inc. traded 46.06% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-thursday-underperforms-market-58f01271-0de85bd06433", "source_name": "MarketWatch", "published_at": "2026-07-09T17:26:00", "published_display": "09 Jul 2026 17:26", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear.", "summary": "Ocugen Inc. (US67577C1053) is a Nasdaq-listed biotechnology company focused on gene-therapy and ophthalmology programs. The company's stock performance is primarily driven by pipeline execution, regulatory milestones, and investor relations communications, rather than fresh catal", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-stock-stays-tied-to-pipeline-progress-nasdaq-listing-keeps-the-us/69716289", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:22:29", "published_display": "07 Jul 2026 17:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data", "summary": "Ocugen Inc. (OCGN) stock rallied 5% after Canaccord initiated coverage with a 'Buy' rating and a $12 price target, indicating a potential 415% upside. The optimism stems from Ocugen's clinical-stage programs for retinal diseases, with analysts noting positive data and upcoming FD", "url": "https://stocktwits.com/news-articles/markets/equity/ocgn-stock-rallies-on-wall-street-optimism-for-clinical-pipeline/cZ3E14YRIXH", "source_name": "Stocktwits", "published_at": "2026-07-05T06:39:20", "published_display": "05 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Ocugen Inc (OCGN)", "summary": "This article analyzes the historical performance of a $1,000 investment in Ocugen Inc (OCGN) over 1, 5, and 10 years, detailing its returns and comparing it against the S&P 500. It also provides an overview of Ocugen Inc's business, focusing on its gene therapy pipeline for blind", "url": "https://www.stocktitan.net/tools/stock-return-calculator/OCGN", "source_name": "Stock Titan", "published_at": "2026-07-04T06:09:29", "published_display": "04 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc outlines its biotech strategy as a Nasdaq-listed micro-cap. Ocugen pursues ophthalmology", "summary": "Ocugen Inc (OCGN) is a Nasdaq-listed, clinical-stage biotechnology company focused on ophthalmology and gene therapy. As a micro-cap, its growth is tied to its developmental pipeline, which targets unmet medical needs in eye-related diseases. The company's strategy involves early", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-inc-outlines-its-biotech-strategy-as-a-nasdaq-listed-micro-cap/69681760", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:58:09", "published_display": "03 Jul 2026 18:58", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Thursday, outperforms market", "summary": "Ocugen Inc. (OCGN) shares rose 2.03% to $1.51 on Thursday, outperforming a mixed market session where the S&P 500 remained largely unchanged and the Dow Jones Industrial Average rose. This increase broke a two-day losing streak for the stock.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-thursday-outperforms-market-cf22cbf9-8a448e496535?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-02T17:24:00", "published_display": "02 Jul 2026 17:24", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen to Participate in Upcoming July Industry Conferences", "summary": "Ocugen, Inc. announced its participation in several investor and industry conferences in July 2026. The biotech company will present on its innovative modifier gene therapy platform for blindness diseases, including presentations at the Piper Sandler Virtual Ophthalmology Day, OI", "url": "https://finance.yahoo.com/healthcare/articles/ocugen-participate-upcoming-july-industry-110000950.html", "source_name": "Market source", "published_at": "2026-07-02T07:09:35", "published_display": "02 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Wednesday, underperforms market", "summary": "Ocugen Inc. (OCGN) shares fell 3.27% to $1.48 on Wednesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for Ocugen's stock.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-wednesday-underperforms-market-562b9a43-10533a81026a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-01T17:27:00", "published_display": "01 Jul 2026 17:27", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen\u2019s July retina conference talks include OCU410 phase 2 results", "summary": "Ocugen (NASDAQ: OCGN) will participate in multiple ophthalmology conferences in July 2026, presenting on its modifier gene therapy platform and retinal disease programs. Key events include the Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and the ASRS mee", "url": "https://www.stocktitan.net/news/OCGN/ocugen-to-participate-in-upcoming-july-industry-l8mnrfwefw2q.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:09:20", "published_display": "01 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Tuesday, underperforms market", "summary": "Ocugen Inc. stock (OCGN) fell by 8.38% on Tuesday, closing at $1.53. This decline occurred despite a positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains. The fall ended a two-day winning streak for Ocugen.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-tuesday-underperforms-market-0bc39321-1835f29ed697?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-30T15:40:33", "published_display": "30 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index", "summary": "Ocugen, Inc. (NasdaqCM: OCGN), a biotechnology company focused on gene therapies, biologics, and vaccines, has been added to the Russell 2000 Index. This inclusion is part of several recent additions to various Russell benchmarks, including the Russell Small Cap Comp Growth, Russ", "url": "https://www.marketscreener.com/news/ocugen-inc-nasdaqcm-ocgn-added-to-russell-2000-index-ce7f5fdfda8cf024", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:52:00", "published_display": "29 Jun 2026 18:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Monday, outperforms market", "summary": "Ocugen Inc. (OCGN) stock increased by 11.33% to $1.67 on Monday, outperforming the broader market. This rise occurred during a positive trading session where the S&P 500 Index and the Dow Jones Industrial Average also saw gains. This marks the second consecutive day of gains for ", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-monday-outperforms-market-6b041ac4-1b61c06a1747?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-06-29T17:29:00", "published_display": "29 Jun 2026 17:29", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Value Benchmark Index", "summary": "Ocugen, Inc. (NasdaqCM: OCGN) has been added to the Russell Microcap Value Benchmark Index. This announcement highlights the company's inclusion in a significant market index, following earlier additions to the Russell 2000 Growth, Russell 3000E Growth, Russell 3000E, and Russell", "url": "https://www.marketscreener.com/news/ocugen-inc-nasdaqcm-ocgn-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989fe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Grinds Higher As Traders Track Tight Range", "summary": "Ocugen, Inc. (OCGN) stock has risen by 8.67% due to optimism over its clinical developments, with its price action showing a shift from a slow grind to a sharper push towards $1.60+. Despite the positive price movement and a pattern of higher lows, the company faces significant f", "url": "https://stockstotrade.com/news/ocugen-inc-ocgn-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T12:32:00", "published_display": "29 Jun 2026 12:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Holds Buy Rating As Analyst Sees Key Catalysts Ahead", "summary": "Ocugen (OCGN) stock is trending up following positive sentiment around its clinical progress, with Canaccord reiterating a Buy rating despite a trimmed price target. The firm highlights strong clinical data in multiple eye diseases and upcoming catalysts as key drivers for the st", "url": "https://stockstotrade.com/news/ocugen-inc-ocgn-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T17:39:51", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Friday, outperforms market", "summary": "Ocugen Inc. stock (OCGN) rose 9.49% to $1.50 on Friday, outperforming the broader market. This occurred despite a dismal trading session where the S&P 500 Index and Dow Jones Industrial Average both fell. The company's stock closed 44.95% below its 52-week high of $2.73, reached ", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-friday-outperforms-market-fbbb0755-f7767f318b6a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-26T17:27:00", "published_display": "26 Jun 2026 17:27", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Ocugen, Inc. \u2013 NASDAQ:OCGN", "summary": "This article focuses on the enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric for Ocugen, Inc. (NASDAQ: OCGN). It appears to be a financial data point from TradingView, indicating a specific valuation multiple for the phar", "url": "https://www.tradingview.com/symbols/NASDAQ-OCGN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:50", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPZkZEMHNDQ0JmTnZmR1c4dnFtRUloQzhLNkFxclh2OWR2Y21MMnhoMWcyUjY0UEN4dFQwamMzcG1wMVp5blprWHl0MU1mSzQxdFpsVC1qRVhnQnh3MnlTYmtPRzBncjBkaGZVV2kycVZsVG5KZjBjNmgyNXdySS03Uk40bVZibWxMMFlsQnhxeURiV0tOTGhnQmRB?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3p1blhROWdnQlYzb19BM0xFZzZURkhudXdBcWtFR0g5ajVmcC1hbXoxeTBCSFotUTlKU3RXemI2UzYyR3o2aUxRdlNkRFozdTVuSzFBR1ZwcjlnNHdjWVRXb3F0WlhBcEwyU0NLU2VONF9iTy1CXzVkNVNNT1dmbHZKN0R2ZEhJemY1ZkhBUkFOcXNuOUJxbXprUjlxYUllU2k5SQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNZzlqOTRpTHJqRDdUVkdBb001ZHJEQkdteWxHeGYzQkF2VFVMeDBPd3NzQ3gzb3EtUERUcmgxRFVkZWpkM0RsaGphb1FYUjJyV2pVQ1dwMVpzYXBJRWtLMS1ZOWlFYXdqNV9iOTRyNnNiNlp3cjRFMkFxNVNzNnNSMW5nY09qN2Rybl9samdVX3pFZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ocugens-gene-agnostic-eye-therapies-155000412.html", "source_name": "Zacks", "published_at": "2026-06-03T15:50:00+00:00", "published_display": "03 Jun 2026 15:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNZS01M2kyZUkyU1VsT0hJd01NaGRBQzRLYWQza2tIZGVYLU9QRFN4RUhzc3czRVQzTzN1YWJCa0V0dlYxWTJDcWF6T2pLZURjNzhaMEJJRFhNX1FnRFpOMUtWQnlWc1JCUW1DRi1sNTQ2LUd3dERoZkxXWTFHRG1Sck5Sb1JCSklIM3RoTklMY3hQOHIxSTlkd3lMQ0lTMHNP?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZml4enp1QTkwb2JYS25oQWg2dkNSbmVvUC1HZHl6WHdhQ0VZRG1Xa1hlZUJkZzZKajlXN0N4WmlJSXRUNndvb191VXVzNm55X21lNHZsVWc4b2RNNUpYTVMzbVNEUDVEZXBkTFhubU45QXE3RWJPcHVBMU9sMFF0LTdHS3c3a2NOSExzSHplQVptd29JMm5LMkNMUlcyaXRVMGphc01lQVNvNE82eV9ZQTFJYkpSNEJaRmtOZFRjQXpRQTVIZE1Tdg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPN1Y0aC1KNzA0X1VsRGRhZ193QlRyT21UVVlDMEx3TWFRdm9kdUJSVVN4RnRtTTNJdENSOEZwNUxpelFoekpyRjVYeVdOZl96emw5ODFSQVZ6eE5Kc3ktcFNxSDhwZzJMZnFuR3lLQkl1T3FPUVNxY2tpLXVxNHJuVUJSaG9XMG5XRGkyNEtDamUtUXZNWEluVmU5UUxZNUJyZHE2YjlnTHgzMGl4dGtEMEVjbjQ1N3k4WGdzR2tidGRwUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX014R0hIbVo0TG8zNlJfelRsVXJzX3ZUQ1BaMjFJZlVmM0VaNFoySXF3eHdTS20zQ2xfOVEyYzZPUDNTYkhFUTduc3hyT21fMEtOREp1MW1YdjdmZk1GUF9CeWtFYnlhbGstbk9ZOHRIc2QteHRDX3FIckRlRnBMMy1kaFM0TFZWRXhTVnEtbEg1TnR5TzVmY0FlYVBFS256ejNFc2tCaklSc2ZFVUd0T1k3TzlfZTdDRTFMalpvX21ZWUIteDRSNw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOc2wtNzJMXzBYdDZjYjJXaWZDMXJWS040bkZGdFZ3eDZVa2FwUTh5TFl6TXQ1VlBEMzNJZTFyR3FNZjVpZVBlQ0RCUmtrMHhSRWwwTGlPZkwwUVZ3TjlMN290Q3FFY0lVTU5WY0NEcGtEWV9PV2JFNXRpdUR2SzF6dnBhME02RHp5NVdndWV4MA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Valuation Check As Loss-Making Q1 2026 And US$103.5m Convertible Notes Reset Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPRlhPUW5zWlVCZ1Z1a2RGcmlXc0lkbXRYUDFvYVJLS3hGa1hIa09lUFNya2JJVDBULUVKSVRJaUk5Z1ZNdTNZUHlCbnV0Qlc1VkQ0dnFROWpBTmNpMWVTd05oUzhGRWlpcm80cmhZNUZHN21hSUItdkNHZXIyVVJEYldJd0puVUF0bVdKR29iNFFhbEpaZk1rZi1uSGoxMmRTaWFUTGxKVV80YlJkbWZ5RVMyZUpmbmc4SElDcVJR?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOUUJFa3hHMmIzYkdTd3dPTVprOXpmNHB5R09aVzZZQmRVb0FKSFRmNmNQWVhXWEV2TEtWZUJJdXRwcHhQRnpXUVFWMlowWnJlTFhDQ09pRFJjeTMtVVVjZ1RhSjFsTnVMeWVOYTVKSWtDdEdKc3h2OWU5MHZhNG50Q21JbExINnhYaVFjNTVjLVJhMDFqbzZj?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVl9EeXFmSU9fM0VLNl9XY3JDaHdnVHpjU243RDNYUktQaGRuczc2N0l6NmJBVUFzUDRPZTJYNGhsckE1V1BGMlFsQWVURXpVLVZycHppR2hibVFTSkF0U1owNzlKMVcwZVV1TlFNZVB2NVNXRW4yZ1RmNWF5VzBxbW9STTZPMFpQUDdVRzFIX3ZGelBuUlpSeG9Wa3dTOUp6ckk0R0pCbGRweHZaR1RsODBmX2d6Ni1rTGNkNWZCQQ?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ocugen sends executives to biotech meetings in Puerto Rico and Rome", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOdW81N2ZwcFFyZEtMcnB0a2VOWFg5ekN4NkhOTDdRMm5rNzVpZUxIcjhhX0xoa19HSHpsckthaldNY1d5RXhUMW80ZW5QbDg5eFd5Si14SzltWXlfNzFnUEE1VzFlWmRUTExiSF9BQkE5Z1RJcktyNHA1Z2w1WHhkb2gyX1BZTmlfdUlKYUVvRTh2Rjk1bGN0aUY2RzFWaXBQcEhVYkFTbmZqQmV6?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQRTk1b2RGdUtabmhJR1hpaWlDMy1YZkEyNFlFYmtBalF5WXJLM1BRZ3FhN0VFZmlrdU5UdzhqQW1kNHU0bGI0TWFqb0JWZTZkZ0NWNzU4YnFoQzB1R1l0U3NScWstZ1NxTExLZ0ZUQ2pQaWR5ak5WTWxIRkx3VVI0RjRhWUxNZHVWZXlURDk4X0otSUZObjVzM3BFXzE5WGpjbFE?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi\u2011Year Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Tanks After Gene Therapy Trial Update \u2014 What Did Ocugen Announce?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOU2Y2QndvUE80UVd5M3FtWUxHMDJYUnBSZ0FpLVlsUndWLXRWdGpnTmgxRkpVVktpZG51RU9TWlJxNlNXZjRhYVVMX2pLMEdEVFgxc3E2QXVhOFFnS0tCajVtN0xtbmFGcUZOV19walQ3bk00eGNDRHE3eEs5andEaEVLZVJhYVZuTDY4WkFUc2Z5al9QUV9EdU8zQjExaVV4WmUtMzd6WllBcWhNbmVLd0d2d0Q2ampoSWRwWUNzR3ZLNnpZZm1aUmpDUkJZUkE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Has A Healthy Cash Position For 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdHR3b3I2bjIwamtyekZfZjFKVFhuSTd3dUoydFRyWGlvU0lqR3I4OEZ1UU9xa2kwMlFfOHpnZWFpeXpTSXJiTXg0bklQWHVnR0FlV2hObzB4YjM4ZVRZUWRDSVRBZ3k1em8zdDlnWTBOa2tMQ2hZUGJuNHh4bnp2OFhOMEtNTHpGdDZmcTZib1dBZU0xQ3NWQUxhR0ZFSFFHMzZhRA?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMVI3ekltcXJLZE9lUjNnWTZmYWhDdy1CRlAwM3pGMTBOLTNHeFpmQ3VQdTNaSUx2c3Fkd3Z1U0w1NkQycGhYNnZfMDhkY0h0cHU3MWE4a3BRZ1o0MlVRUTFjTXRDaFk2aHU1Y29xalFybkVGNHV1OXZ5Tmw2X0s3QlBNbkNydFRZQzZZMXhOYXc5YUl6aEk3OU10YVk?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBBS1Z4Y0dOdENWcU5qUVdjSnlVZDhDWWdIMWxuYjZlWW05TFA2My1nRG1fSkJUX0RCOTBGQlhFWHJmS2RoMVJxckRoS3FZRUh1cGNycGZ5aDNESEVoOWhPczlkOFU2NHlGRkpBaU12LW11QzRjWHpqLUhCNA?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbzQwWElpUVRmX0MzTXA4aE5BQy15MHM4OGMyXzl4TzU5bS1aTEZtQm1KYlZHSkpSTFFuUm43dDY0OVhTcHVPdzdZNmExUTZRNm1sWU1QSU83cG81QUFwVVNDQXh5ZndJRmZzc0s5N2hkb01abi1rY1ZxZkdDOGx1MkxyVnAyVlVESHJhNUZSR1VuR2V3ZnlXTFlyNkgzQ0RWbEhfbGlWQ29FaURIbGI3ZEROTWZxVzQ?oc=5", "source_name": "TradingView", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN2JGd2tSUFRRcGx5T3pLVXBsVG9TVHNWTUtZd1ItN3hidnNMT2tBZXp0a0xhYTF3TEdVQTQ3WnVzYnY2WW0xQ1lmOFAwWUJwM1FRVjRkak1FNm5JajZXMVpVeUh5aFBTS2MzSzNfaTBVZUNOX0hodEoyaHNzSkgxYjRrdlBmampOcDVMVTlhMWo1eGhfR3RPWFNJd0lHZHFyblVzZEpYenFpM0FHeUdDbVdreEx6RTg?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Provides Business Update with Second Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSHZqdmFvcWx2WTBIQmc4MmRjNTFTUTZ3TG5ibkIzX01qRVJOeXpuMVNWOTN5TG00QTd3dlNqQ2wyeUkzcXZPV2tjVU8zeXhOQm02NFN0YXBJbDdudGF5MF81NjRCSmlraXlLcV9HRE16Y29OX25Hc0JvNFR1UERXRjJWRGVPQmM5d0xBeDVfekJGejBiS2hJeUFoeTlodUpOdGNILUxnNHNmWER6Tlo5TnM5WWZpNXBvSW00?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ocugen Inc. stock rises Tuesday, outperforms market", "summary": "Shares of Ocugen Inc. (OCGN) rose on Tuesday, gaining 1.42% to close at $1.43. This performance outpaced the broader market, as the S&P 500 Index and the Dow Jones Industrial Average also saw increases. Despite the rise, Ocugen Inc. remains 47.52% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-tuesday-outperforms-market-3f5a5f8d-f9b41f6b5309", "source_name": "MarketWatch", "published_at": "2026-07-14T17:27:00", "published_display": "14 Jul 2026 17:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Monday, underperforms market", "summary": "Ocugen Inc. (OCGN) stock fell 4.08% on Monday, closing at $1.41, underperforming the broader market as the S&P 500 and Dow Jones also experienced declines. The company's stock is currently 48.26% below its 52-week high of $2.73, achieved on March 17th.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-monday-underperforms-market-a13eca2e-cc40f435f2ea", "source_name": "MarketWatch", "published_at": "2026-07-13T17:28:00", "published_display": "13 Jul 2026 17:28", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa", "summary": "Ocugen, Inc. has announced a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license OCU400, a modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. The agreement includes potential sales mileston", "url": "https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-binding-term-sheet-roots-pharmaceutical/", "source_name": "Ocugen, Inc.", "published_at": "2026-07-13T15:10:42", "published_display": "13 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbnQtNVJfQ3A3SFUxMUp2OUxaaUNuWDNINFU2NXZqWDJZWE9ZcHVIdnhyZkZfNHYxVUNGcTE3d2taanN5dHd1ekZaLVRaYUxIQS0yMWhqdHRtV3pSenZUUjNDZ0xwYWtRMXdkRWE5MHpqWnlzRXZKM1FqZHdJcmVYcnpiZlM4Y04zQ3NRT190LWxBQ3BDdFpZRGdvZVQwX0daTC04Rk4wZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T12:07:18+00:00", "published_display": "13 Jul 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region", "summary": "Ocugen has signed a term sheet to license its retinitis pigmentosa gene therapy, OCU400, to Roots Pharmaceutical and Al-Dhow for commercialization in the MENA region. This agreement, facilitated by a joint venture between the two MENA companies, aims to bring OCU400 to patients w", "url": "https://www.moomoo.com/news/post/72859257/ocugen-signs-term-sheet-to-license-retinitis-pigmentosa-gene-therapy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T12:10:43", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Ocugen, Inc. Reports Material Event", "summary": "Ocugen, Inc. announced it has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to negotiate an exclusive license for its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa. The deal could bring Ocugen u", "url": "https://www.stocktitan.net/sec-filings/OCGN/8-k-ocugen-inc-reports-material-event-8b91c8a4fa57.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:42", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen signs OCU400 MENA license agreement", "summary": "Ocugen has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding for the exclusive licensing rights of its investigational gene therapy OCU400 in the Middle East and North Africa (MENA) region. This potential agreement could bring Ocugen up to $4", "url": "https://grafa.com/en/news/united-states/ocugen-ocu400-mena-license-agreement-retinitis-pigmentosa", "source_name": "grafa.com", "published_at": "2026-07-13T11:38:00", "published_display": "13 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene therapy for inherited blindness set for MENA launch under Ocugen\u2013Roots pact", "summary": "Ocugen (NASDAQ: OCGN) has signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa (MENA) region. The agreement is expected to include up to $4 ", "url": "https://www.stocktitan.net/news/OCGN/ocugen-inc-announces-binding-term-sheet-with-roots-pharmaceutical-to-2xzd3dhb2bm7.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:10:43", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances", "summary": "Ocugen (NASDAQ:OCGN) plans to submit three biologics license applications (BLAs) for its late-stage retinal gene therapies, targeting retinitis pigmentosa and Stargardt disease next year, and geographic atrophy in 2028. The company expects to deliver two top-line readouts in 2025", "url": "https://finance.yahoo.com/healthcare/articles/ocugen-eyes-3-retinal-gene-000206047.html", "source_name": "Market source", "published_at": "2026-07-11T00:09:47", "published_display": "11 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Thursday, underperforms market", "summary": "Ocugen Inc. (OCGN) stock fell 2.00% on Thursday, closing at $1.47, despite an overall positive trading day for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, while Ocugen Inc. traded 46.06% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-thursday-underperforms-market-58f01271-0de85bd06433", "source_name": "MarketWatch", "published_at": "2026-07-09T17:26:00", "published_display": "09 Jul 2026 17:26", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear.", "summary": "Ocugen Inc. (US67577C1053) is a Nasdaq-listed biotechnology company focused on gene-therapy and ophthalmology programs. The company's stock performance is primarily driven by pipeline execution, regulatory milestones, and investor relations communications, rather than fresh catal", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-stock-stays-tied-to-pipeline-progress-nasdaq-listing-keeps-the-us/69716289", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:22:29", "published_display": "07 Jul 2026 17:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data", "summary": "Ocugen Inc. (OCGN) stock rallied 5% after Canaccord initiated coverage with a 'Buy' rating and a $12 price target, indicating a potential 415% upside. The optimism stems from Ocugen's clinical-stage programs for retinal diseases, with analysts noting positive data and upcoming FD", "url": "https://stocktwits.com/news-articles/markets/equity/ocgn-stock-rallies-on-wall-street-optimism-for-clinical-pipeline/cZ3E14YRIXH", "source_name": "Stocktwits", "published_at": "2026-07-05T06:39:20", "published_display": "05 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Ocugen Inc (OCGN)", "summary": "This article analyzes the historical performance of a $1,000 investment in Ocugen Inc (OCGN) over 1, 5, and 10 years, detailing its returns and comparing it against the S&P 500. It also provides an overview of Ocugen Inc's business, focusing on its gene therapy pipeline for blind", "url": "https://www.stocktitan.net/tools/stock-return-calculator/OCGN", "source_name": "Stock Titan", "published_at": "2026-07-04T06:09:29", "published_display": "04 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc outlines its biotech strategy as a Nasdaq-listed micro-cap. Ocugen pursues ophthalmology", "summary": "Ocugen Inc (OCGN) is a Nasdaq-listed, clinical-stage biotechnology company focused on ophthalmology and gene therapy. As a micro-cap, its growth is tied to its developmental pipeline, which targets unmet medical needs in eye-related diseases. The company's strategy involves early", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-inc-outlines-its-biotech-strategy-as-a-nasdaq-listed-micro-cap/69681760", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T18:58:09", "published_display": "03 Jul 2026 18:58", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Thursday, outperforms market", "summary": "Ocugen Inc. (OCGN) shares rose 2.03% to $1.51 on Thursday, outperforming a mixed market session where the S&P 500 remained largely unchanged and the Dow Jones Industrial Average rose. This increase broke a two-day losing streak for the stock.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-thursday-outperforms-market-cf22cbf9-8a448e496535?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-02T17:24:00", "published_display": "02 Jul 2026 17:24", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen to Participate in Upcoming July Industry Conferences", "summary": "Ocugen, Inc. announced its participation in several investor and industry conferences in July 2026. The biotech company will present on its innovative modifier gene therapy platform for blindness diseases, including presentations at the Piper Sandler Virtual Ophthalmology Day, OI", "url": "https://finance.yahoo.com/healthcare/articles/ocugen-participate-upcoming-july-industry-110000950.html", "source_name": "Market source", "published_at": "2026-07-02T07:09:35", "published_display": "02 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Wednesday, underperforms market", "summary": "Ocugen Inc. (OCGN) shares fell 3.27% to $1.48 on Wednesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for Ocugen's stock.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-wednesday-underperforms-market-562b9a43-10533a81026a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-01T17:27:00", "published_display": "01 Jul 2026 17:27", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen\u2019s July retina conference talks include OCU410 phase 2 results", "summary": "Ocugen (NASDAQ: OCGN) will participate in multiple ophthalmology conferences in July 2026, presenting on its modifier gene therapy platform and retinal disease programs. Key events include the Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and the ASRS mee", "url": "https://www.stocktitan.net/news/OCGN/ocugen-to-participate-in-upcoming-july-industry-l8mnrfwefw2q.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:09:20", "published_display": "01 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock falls Tuesday, underperforms market", "summary": "Ocugen Inc. stock (OCGN) fell by 8.38% on Tuesday, closing at $1.53. This decline occurred despite a positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains. The fall ended a two-day winning streak for Ocugen.", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-falls-tuesday-underperforms-market-0bc39321-1835f29ed697?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-30T15:40:33", "published_display": "30 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index", "summary": "Ocugen, Inc. (NasdaqCM: OCGN), a biotechnology company focused on gene therapies, biologics, and vaccines, has been added to the Russell 2000 Index. This inclusion is part of several recent additions to various Russell benchmarks, including the Russell Small Cap Comp Growth, Russ", "url": "https://www.marketscreener.com/news/ocugen-inc-nasdaqcm-ocgn-added-to-russell-2000-index-ce7f5fdfda8cf024", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:52:00", "published_display": "29 Jun 2026 18:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Monday, outperforms market", "summary": "Ocugen Inc. (OCGN) stock increased by 11.33% to $1.67 on Monday, outperforming the broader market. This rise occurred during a positive trading session where the S&P 500 Index and the Dow Jones Industrial Average also saw gains. This marks the second consecutive day of gains for ", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-monday-outperforms-market-6b041ac4-1b61c06a1747?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-06-29T17:29:00", "published_display": "29 Jun 2026 17:29", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Value Benchmark Index", "summary": "Ocugen, Inc. (NasdaqCM: OCGN) has been added to the Russell Microcap Value Benchmark Index. This announcement highlights the company's inclusion in a significant market index, following earlier additions to the Russell 2000 Growth, Russell 3000E Growth, Russell 3000E, and Russell", "url": "https://www.marketscreener.com/news/ocugen-inc-nasdaqcm-ocgn-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989fe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Grinds Higher As Traders Track Tight Range", "summary": "Ocugen, Inc. (OCGN) stock has risen by 8.67% due to optimism over its clinical developments, with its price action showing a shift from a slow grind to a sharper push towards $1.60+. Despite the positive price movement and a pattern of higher lows, the company faces significant f", "url": "https://stockstotrade.com/news/ocugen-inc-ocgn-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T12:32:00", "published_display": "29 Jun 2026 12:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Holds Buy Rating As Analyst Sees Key Catalysts Ahead", "summary": "Ocugen (OCGN) stock is trending up following positive sentiment around its clinical progress, with Canaccord reiterating a Buy rating despite a trimmed price target. The firm highlights strong clinical data in multiple eye diseases and upcoming catalysts as key drivers for the st", "url": "https://stockstotrade.com/news/ocugen-inc-ocgn-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T17:39:51", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc. stock rises Friday, outperforms market", "summary": "Ocugen Inc. stock (OCGN) rose 9.49% to $1.50 on Friday, outperforming the broader market. This occurred despite a dismal trading session where the S&P 500 Index and Dow Jones Industrial Average both fell. The company's stock closed 44.95% below its 52-week high of $2.73, reached ", "url": "https://www.marketwatch.com/data-news/ocugen-inc-stock-rises-friday-outperforms-market-fbbb0755-f7767f318b6a?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-26T17:27:00", "published_display": "26 Jun 2026 17:27", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Ocugen, Inc. \u2013 NASDAQ:OCGN", "summary": "This article focuses on the enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric for Ocugen, Inc. (NASDAQ: OCGN). It appears to be a financial data point from TradingView, indicating a specific valuation multiple for the phar", "url": "https://www.tradingview.com/symbols/NASDAQ-OCGN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:50", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPZkZEMHNDQ0JmTnZmR1c4dnFtRUloQzhLNkFxclh2OWR2Y21MMnhoMWcyUjY0UEN4dFQwamMzcG1wMVp5blprWHl0MU1mSzQxdFpsVC1qRVhnQnh3MnlTYmtPRzBncjBkaGZVV2kycVZsVG5KZjBjNmgyNXdySS03Uk40bVZibWxMMFlsQnhxeURiV0tOTGhnQmRB?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3p1blhROWdnQlYzb19BM0xFZzZURkhudXdBcWtFR0g5ajVmcC1hbXoxeTBCSFotUTlKU3RXemI2UzYyR3o2aUxRdlNkRFozdTVuSzFBR1ZwcjlnNHdjWVRXb3F0WlhBcEwyU0NLU2VONF9iTy1CXzVkNVNNT1dmbHZKN0R2ZEhJemY1ZkhBUkFOcXNuOUJxbXprUjlxYUllU2k5SQ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNZzlqOTRpTHJqRDdUVkdBb001ZHJEQkdteWxHeGYzQkF2VFVMeDBPd3NzQ3gzb3EtUERUcmgxRFVkZWpkM0RsaGphb1FYUjJyV2pVQ1dwMVpzYXBJRWtLMS1ZOWlFYXdqNV9iOTRyNnNiNlp3cjRFMkFxNVNzNnNSMW5nY09qN2Rybl9samdVX3pFZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ocugens-gene-agnostic-eye-therapies-155000412.html", "source_name": "Zacks", "published_at": "2026-06-03T15:50:00+00:00", "published_display": "03 Jun 2026 15:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNZS01M2kyZUkyU1VsT0hJd01NaGRBQzRLYWQza2tIZGVYLU9QRFN4RUhzc3czRVQzTzN1YWJCa0V0dlYxWTJDcWF6T2pLZURjNzhaMEJJRFhNX1FnRFpOMUtWQnlWc1JCUW1DRi1sNTQ2LUd3dERoZkxXWTFHRG1Sck5Sb1JCSklIM3RoTklMY3hQOHIxSTlkd3lMQ0lTMHNP?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZml4enp1QTkwb2JYS25oQWg2dkNSbmVvUC1HZHl6WHdhQ0VZRG1Xa1hlZUJkZzZKajlXN0N4WmlJSXRUNndvb191VXVzNm55X21lNHZsVWc4b2RNNUpYTVMzbVNEUDVEZXBkTFhubU45QXE3RWJPcHVBMU9sMFF0LTdHS3c3a2NOSExzSHplQVptd29JMm5LMkNMUlcyaXRVMGphc01lQVNvNE82eV9ZQTFJYkpSNEJaRmtOZFRjQXpRQTVIZE1Tdg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPN1Y0aC1KNzA0X1VsRGRhZ193QlRyT21UVVlDMEx3TWFRdm9kdUJSVVN4RnRtTTNJdENSOEZwNUxpelFoekpyRjVYeVdOZl96emw5ODFSQVZ6eE5Kc3ktcFNxSDhwZzJMZnFuR3lLQkl1T3FPUVNxY2tpLXVxNHJuVUJSaG9XMG5XRGkyNEtDamUtUXZNWEluVmU5UUxZNUJyZHE2YjlnTHgzMGl4dGtEMEVjbjQ1N3k4WGdzR2tidGRwUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX014R0hIbVo0TG8zNlJfelRsVXJzX3ZUQ1BaMjFJZlVmM0VaNFoySXF3eHdTS20zQ2xfOVEyYzZPUDNTYkhFUTduc3hyT21fMEtOREp1MW1YdjdmZk1GUF9CeWtFYnlhbGstbk9ZOHRIc2QteHRDX3FIckRlRnBMMy1kaFM0TFZWRXhTVnEtbEg1TnR5TzVmY0FlYVBFS256ejNFc2tCaklSc2ZFVUd0T1k3TzlfZTdDRTFMalpvX21ZWUIteDRSNw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOc2wtNzJMXzBYdDZjYjJXaWZDMXJWS040bkZGdFZ3eDZVa2FwUTh5TFl6TXQ1VlBEMzNJZTFyR3FNZjVpZVBlQ0RCUmtrMHhSRWwwTGlPZkwwUVZ3TjlMN290Q3FFY0lVTU5WY0NEcGtEWV9PV2JFNXRpdUR2SzF6dnBhME02RHp5NVdndWV4MA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Valuation Check As Loss-Making Q1 2026 And US$103.5m Convertible Notes Reset Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPRlhPUW5zWlVCZ1Z1a2RGcmlXc0lkbXRYUDFvYVJLS3hGa1hIa09lUFNya2JJVDBULUVKSVRJaUk5Z1ZNdTNZUHlCbnV0Qlc1VkQ0dnFROWpBTmNpMWVTd05oUzhGRWlpcm80cmhZNUZHN21hSUItdkNHZXIyVVJEYldJd0puVUF0bVdKR29iNFFhbEpaZk1rZi1uSGoxMmRTaWFUTGxKVV80YlJkbWZ5RVMyZUpmbmc4SElDcVJR?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOUUJFa3hHMmIzYkdTd3dPTVprOXpmNHB5R09aVzZZQmRVb0FKSFRmNmNQWVhXWEV2TEtWZUJJdXRwcHhQRnpXUVFWMlowWnJlTFhDQ09pRFJjeTMtVVVjZ1RhSjFsTnVMeWVOYTVKSWtDdEdKc3h2OWU5MHZhNG50Q21JbExINnhYaVFjNTVjLVJhMDFqbzZj?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQVl9EeXFmSU9fM0VLNl9XY3JDaHdnVHpjU243RDNYUktQaGRuczc2N0l6NmJBVUFzUDRPZTJYNGhsckE1V1BGMlFsQWVURXpVLVZycHppR2hibVFTSkF0U1owNzlKMVcwZVV1TlFNZVB2NVNXRW4yZ1RmNWF5VzBxbW9STTZPMFpQUDdVRzFIX3ZGelBuUlpSeG9Wa3dTOUp6ckk0R0pCbGRweHZaR1RsODBmX2d6Ni1rTGNkNWZCQQ?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen sends executives to biotech meetings in Puerto Rico and Rome", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOdW81N2ZwcFFyZEtMcnB0a2VOWFg5ekN4NkhOTDdRMm5rNzVpZUxIcjhhX0xoa19HSHpsckthaldNY1d5RXhUMW80ZW5QbDg5eFd5Si14SzltWXlfNzFnUEE1VzFlWmRUTExiSF9BQkE5Z1RJcktyNHA1Z2w1WHhkb2gyX1BZTmlfdUlKYUVvRTh2Rjk1bGN0aUY2RzFWaXBQcEhVYkFTbmZqQmV6?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQRTk1b2RGdUtabmhJR1hpaWlDMy1YZkEyNFlFYmtBalF5WXJLM1BRZ3FhN0VFZmlrdU5UdzhqQW1kNHU0bGI0TWFqb0JWZTZkZ0NWNzU4YnFoQzB1R1l0U3NScWstZ1NxTExLZ0ZUQ2pQaWR5ak5WTWxIRkx3VVI0RjRhWUxNZHVWZXlURDk4X0otSUZObjVzM3BFXzE5WGpjbFE?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi\u2011Year Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OCGN Stock Tanks After Gene Therapy Trial Update \u2014 What Did Ocugen Announce?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOU2Y2QndvUE80UVd5M3FtWUxHMDJYUnBSZ0FpLVlsUndWLXRWdGpnTmgxRkpVVktpZG51RU9TWlJxNlNXZjRhYVVMX2pLMEdEVFgxc3E2QXVhOFFnS0tCajVtN0xtbmFGcUZOV19walQ3bk00eGNDRHE3eEs5andEaEVLZVJhYVZuTDY4WkFUc2Z5al9QUV9EdU8zQjExaVV4WmUtMzd6WllBcWhNbmVLd0d2d0Q2ampoSWRwWUNzR3ZLNnpZZm1aUmpDUkJZUkE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN) Has A Healthy Cash Position For 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdHR3b3I2bjIwamtyekZfZjFKVFhuSTd3dUoydFRyWGlvU0lqR3I4OEZ1UU9xa2kwMlFfOHpnZWFpeXpTSXJiTXg0bklQWHVnR0FlV2hObzB4YjM4ZVRZUWRDSVRBZ3k1em8zdDlnWTBOa2tMQ2hZUGJuNHh4bnp2OFhOMEtNTHpGdDZmcTZib1dBZU0xQ3NWQUxhR0ZFSFFHMzZhRA?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNMVI3ekltcXJLZE9lUjNnWTZmYWhDdy1CRlAwM3pGMTBOLTNHeFpmQ3VQdTNaSUx2c3Fkd3Z1U0w1NkQycGhYNnZfMDhkY0h0cHU3MWE4a3BRZ1o0MlVRUTFjTXRDaFk2aHU1Y29xalFybkVGNHV1OXZ5Tmw2X0s3QlBNbkNydFRZQzZZMXhOYXc5YUl6aEk3OU10YVk?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFBBS1Z4Y0dOdENWcU5qUVdjSnlVZDhDWWdIMWxuYjZlWW05TFA2My1nRG1fSkJUX0RCOTBGQlhFWHJmS2RoMVJxckRoS3FZRUh1cGNycGZ5aDNESEVoOWhPczlkOFU2NHlGRkpBaU12LW11QzRjWHpqLUhCNA?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbzQwWElpUVRmX0MzTXA4aE5BQy15MHM4OGMyXzl4TzU5bS1aTEZtQm1KYlZHSkpSTFFuUm43dDY0OVhTcHVPdzdZNmExUTZRNm1sWU1QSU83cG81QUFwVVNDQXh5ZndJRmZzc0s5N2hkb01abi1rY1ZxZkdDOGx1MkxyVnAyVlVESHJhNUZSR1VuR2V3ZnlXTFlyNkgzQ0RWbEhfbGlWQ29FaURIbGI3ZEROTWZxVzQ?oc=5", "source_name": "TradingView", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN2JGd2tSUFRRcGx5T3pLVXBsVG9TVHNWTUtZd1ItN3hidnNMT2tBZXp0a0xhYTF3TEdVQTQ3WnVzYnY2WW0xQ1lmOFAwWUJwM1FRVjRkak1FNm5JajZXMVpVeUh5aFBTS2MzSzNfaTBVZUNOX0hodEoyaHNzSkgxYjRrdlBmampOcDVMVTlhMWo1eGhfR3RPWFNJd0lHZHFyblVzZEpYenFpM0FHeUdDbVdreEx6RTg?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ocugen Provides Business Update with Second Quarter 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSHZqdmFvcWx2WTBIQmc4MmRjNTFTUTZ3TG5ibkIzX01qRVJOeXpuMVNWOTN5TG00QTd3dlNqQ2wyeUkzcXZPV2tjVU8zeXhOQm02NFN0YXBJbDdudGF5MF81NjRCSmlraXlLcV9HRE16Y29OX25Hc0JvNFR1UERXRjJWRGVPQmM5d0xBeDVfekJGejBiS2hJeUFoeTlodUpOdGNILUxnNHNmWER6Tlo5TnM5WWZpNXBvSW00?oc=5", "source_name": "Ocugen, Inc.", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 61, "sentiment_summary": {"positive": 22, "negative": 8, "neutral": 31, "score": 55, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 22.4, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 22, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 1.47, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": 21.5, "twelve_week_move": -26.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.674969, "market_dynamics_buy_signal": false, "relative_strength": -13.076356, "fair_value_gap": 35.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.5856, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, +21.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "MarketWatch", "count": 8}, {"label": "simplywall.st", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "Ocugen, Inc.", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "9", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.6% over one week, +21.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Ocugen Inc. stock rises Tuesday, outperforms market"}], "updated_at": "2026-07-16T10:35:18.710533+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}